Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulants in pregnancy.

Ian A Greer1

  • 1Division of Developmental Medicine, Maternal and Reproductive Medicine, Glasgow Royal Infirmary, University of Glasgow, 10 Alexandra Parade, Glasgow G31 2ER, Scotland, U.K. I.A.Greer@clinmed.gla.ac.uk

Journal of Thrombosis and Thrombolysis
|February 14, 2006
PubMed
Summary

Low-molecular-weight heparin (LMWH) offers a safer and more convenient alternative to unfractionated heparin for preventing and treating venous thromboembolism (VTE) during pregnancy. LMWH demonstrates improved safety and efficacy, reducing maternal mortality risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment-based management of placenta-mediated pregnancy complications: Pragmatism until a precision medicine approach evolves.

British journal of haematology·2023
Same author

United Kingdom recommendations for obstetric venous thromboembolism prophylaxis: Evidence and rationale.

Seminars in perinatology·2019
Same author

American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

Blood advances·2018
Same author

'To test or not to test', the arguments for and against thrombophilia testing in obstetrics.

Obstetric medicine·2017
Same author

LMWH in IVF - Biomarkers and benefits.

Thrombosis research·2017
Same author

Low-molecular-weight heparin for pregnancy complications.

Lancet (London, England)·2016

Area of Science:

  • Obstetrics and Gynecology
  • Hematology
  • Pharmacology

Background:

  • Venous thromboembolism (VTE) is a significant cause of maternal mortality globally.
  • Current anticoagulation in pregnancy relies on heparinoids due to coumarin's teratogenicity and fetal risks.
  • Effective VTE management requires understanding risk factors and appropriate thromboprophylaxis.

Purpose of the Study:

  • To review the safety and efficacy of low-molecular-weight heparin (LMWH) in pregnancy.
  • To compare LMWH with unfractionated heparin (UFH) for obstetric anticoagulation.
  • To highlight LMWH's role in preventing pregnancy complications beyond VTE.

Main Methods:

  • Review of existing clinical data and experience with LMWH in pregnant populations.
  • Comparative analysis of safety profiles (osteoporosis, heparin-induced thrombocytopenia) and convenience between LMWH and UFH.

Related Experiment Videos

  • Assessment of LMWH's expanding clinical applications in obstetric care.

    • Main Results:

    • Extensive experience confirms the safety and efficacy of LMWH during pregnancy.
    • LMWH offers significant advantages over UFH, including a lower incidence of osteoporosis and heparin-induced thrombocytopenia.
    • Once-daily dosing of LMWH enhances patient convenience and adherence.

    Conclusions:

    • LMWH is the preferred anticoagulant for VTE prevention and treatment in pregnancy.
    • LMWH provides a superior safety profile and improved patient experience compared to UFH.
    • LMWH's therapeutic potential is being explored for other pregnancy-related complications.